tiprankstipranks
Trending News
More News >
Amrize Ltd (AMRZ)
NYSE:AMRZ
US Market
Advertisement

Amrize Ltd (AMRZ) AI Stock Analysis

Compare
59 Followers

Top Page

AMRZ

Amrize Ltd

(NYSE:AMRZ)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
$56.00
▲(7.75% Upside)
Amrize Ltd's overall stock score reflects strong financial performance and positive earnings call sentiment as the most significant factors. Technical analysis and valuation present moderate risks, but the company's robust financial health and optimistic future outlook support a favorable score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates robust market demand and effective business strategies, supporting long-term expansion and stability.
Margin Expansion
Sustained margin expansion reflects operational efficiency and cost management, enhancing profitability and competitive positioning.
Debt Management
Improved debt management enhances financial flexibility and reduces risk, supporting long-term financial health and investment capacity.
Negative Factors
Cash Flow Challenges
Negative free cash flow growth may constrain future investments and operational flexibility, impacting long-term growth prospects.
Cement Network Outage
Operational disruptions can lead to increased costs and affect profitability, highlighting potential vulnerabilities in infrastructure.
Residential Construction Softness
Weakness in residential construction may limit growth in related segments, affecting overall revenue and market position.

Amrize Ltd (AMRZ) vs. SPDR S&P 500 ETF (SPY)

Amrize Ltd Business Overview & Revenue Model

Company DescriptionAmrize Ltd (AMRZ) is a technology-driven company specializing in innovative solutions for the healthcare and wellness sectors. Focused on improving patient outcomes and enhancing the efficiency of healthcare delivery, Amrize offers a range of products and services, including telehealth platforms, electronic health records (EHR) systems, and integrated health management solutions. Through its advanced technology, the company aims to streamline healthcare processes and empower both providers and patients.
How the Company Makes MoneyAmrize Ltd generates revenue primarily through the sale of its software solutions and subscription-based services. The core revenue streams include licensing fees from healthcare providers for the use of its telehealth platforms and EHR systems, as well as recurring subscription fees for ongoing support and updates. Additionally, the company has established strategic partnerships with various healthcare organizations and technology firms, which not only enhance its product offerings but also contribute to increased market reach and customer acquisition. These collaborations often result in joint ventures or revenue-sharing agreements that further bolster Amrize's earnings.

Amrize Ltd Earnings Call Summary

Earnings Call Date:Oct 28, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth and free cash flow, successful margin expansion in Building Envelope, and progress in the ASPIRE synergy program, alongside a positive demand outlook. However, challenges included a temporary equipment outage in the cement network, softness in residential construction, and cement pricing pressure.
Q3-2025 Updates
Positive Updates
Strong Revenue Growth
Amrize delivered strong revenue growth of 6.6%, driven by continued infrastructure demand and an improving commercial market.
Free Cash Flow Increase
The company generated strong free cash flow of $674 million, up $221 million from the prior year.
Successful Margin Expansion
Building Envelope business delivered substantial margin expansion driven by operational efficiencies and lower raw material costs.
Project ASPIRE Progress
Excellent progress in the ASPIRE synergy program with over 300 new logistics and service providers onboarded and more than 100 projects launched.
Positive Demand Outlook
Raising 2025 revenue guidance with strong long-term demand expected from infrastructure, modernization, and data center expansion.
Negative Updates
Cement Network Equipment Outage
Temporary equipment outage in the cement network resulted in approximately $50 million of higher manufacturing and distribution costs.
Year-over-Year Adjusted EBITDA Comparison Impact
The comparison was affected by a material asset sale in the third quarter of last year.
Residential Construction Softness
Residential volumes were down due to soft new construction activity and a milder storm season.
Cement Pricing Pressure
Cement pricing for the quarter was down 0.6%, reflecting softer demand.
Company Guidance
During the Amrize Q3 2025 earnings call, the company provided guidance and updates on several performance metrics. Amrize reported a 6.6% increase in revenue, driven by infrastructure demand and improvement in the commercial market. Despite a temporary equipment outage in the cement network causing higher costs, the company achieved strong free cash flow of $674 million, up $221 million from the previous year. Building Materials revenue rose by 8.7%, with cement volumes increasing by 6% and aggregates by 3.3%. The Building Envelope segment saw a 0.7% revenue increase, with adjusted EBITDA margins expanding by 190 basis points due to operational efficiencies and lower raw material costs. The company confirmed its adjusted EBITDA guidance for the year at $2.9 billion to $3.1 billion and expects a net leverage ratio below 1.5x. Amrize continues to invest in organic growth projects, including expansions at its Ste. Gen and St. Constant plants. Looking forward, the company remains optimistic about long-term demand driven by megatrends like infrastructure modernization and data center expansion.

Amrize Ltd Financial Statement Overview

Summary
Amrize Ltd exhibits strong financial health with improving profitability and leverage metrics. The company has effectively managed its debt levels while maintaining robust margins. Despite a temporary dip in free cash flow growth, the cash flow position remains solid, supporting future growth prospects.
Income Statement
85
Very Positive
Amrize Ltd has demonstrated strong profitability with a consistent increase in gross profit margin from 23.05% in 2022 to 26.23% in 2024. The net profit margin also improved significantly from 8.19% in 2023 to 12.12% in 2024, indicating enhanced operational efficiency. Revenue growth has been steady, with a notable increase of 8.87% in 2023. EBIT and EBITDA margins have shown positive trends, reflecting robust core business performance.
Balance Sheet
78
Positive
The company's balance sheet indicates a solid financial position with a declining debt-to-equity ratio from 1.05 in 2022 to 0.43 in 2024, suggesting improved leverage management. Return on equity remains stable, showcasing effective use of shareholder funds. The equity ratio is not explicitly provided, but the reduction in debt levels enhances financial stability.
Cash Flow
72
Positive
Amrize Ltd's cash flow analysis shows a healthy operating cash flow to net income ratio, improving from 0.83 in 2023 to 0.94 in 2024. However, free cash flow growth was negative in 2023, indicating potential challenges in cash generation. The free cash flow to net income ratio remains strong, reflecting efficient cash conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue8.98B11.70B11.68B10.73B
Gross Profit2.27B3.07B2.77B2.47B
EBITDA2.10B3.01B2.70B2.50B
Net Income919.00M1.42B956.00M1.11B
Balance Sheet
Total Assets24.04B23.52B23.05B20.67B
Cash, Cash Equivalents and Short-Term Investments826.00M1.82B1.11B351.00M
Total Debt6.44B5.79B9.52B8.66B
Total Liabilities11.14B10.21B13.84B12.46B
Stockholders Equity12.90B13.31B9.20B8.21B
Cash Flow
Free Cash Flow-227.00M1.64B1.41B1.50B
Operating Cash Flow404.00M2.28B2.04B1.99B
Investing Cash Flow-211.00M-1.21B-2.02B-2.52B
Financing Cash Flow-978.00M-537.00M734.00M497.00M

Amrize Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$15.37B11.047.10%0.85%-5.68%210.34%
$36.97B34.1812.10%0.52%1.02%-45.31%
$28.73B
$38.32B41.2311.89%0.66%0.19%4.33%
$2.76B15.2727.89%1.02%16.89%24.91%
$12.59B28.2715.80%-4.74%-33.79%
$10.43B7.12-0.05%2.87%2.86%-36.73%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMRZ
Amrize Ltd
51.97
-1.03
-1.94%
CX
Cemex SAB
10.13
5.01
97.85%
MLM
Martin Marietta Materials
613.02
36.20
6.28%
VMC
Vulcan Materials
289.50
21.10
7.86%
TGLS
Tecnoglass
58.77
-9.18
-13.51%
JHX
James Hardie Industries PLC
21.11
-7.24
-25.54%

Amrize Ltd Corporate Events

Amrize Ltd Reports Stable Q3 2025 Earnings
Oct 30, 2025

Amrize Ltd is a building solutions company based in Switzerland, focusing on the North American market, and offers a range of products from cement to advanced roofing systems. In its latest earnings report for the quarter ending September 30, 2025, Amrize Ltd reported revenues of $3.675 billion, an increase from the previous year, with a net income of $543 million. The company has undergone a significant transition following its spin-off from Holcim Ltd, becoming an independent public entity. Key financial metrics indicate a stable performance with a gross profit of $1.086 billion and operating income of $778 million. Despite a slight decrease in net income compared to the previous year, the company has managed to maintain a strong equity position with $12.901 billion in equity attributable to the company. Looking forward, Amrize Ltd aims to continue its growth trajectory in the building solutions market, leveraging its recent acquisitions and strategic initiatives to enhance its market presence.

Amrize Ltd Reports Robust Growth Amid Challenges
Oct 30, 2025

The recent earnings call of Amrize Ltd painted a picture of robust growth and strategic advancements, albeit with some operational challenges. The overall sentiment was positive, buoyed by strong revenue growth and free cash flow, successful margin expansion in the Building Envelope segment, and progress in the ASPIRE synergy program. However, the company also faced hurdles such as a temporary equipment outage in the cement network and pricing pressures.

Amrize Ltd Reports Strong Q3 Revenue Growth Amid Strategic Investments
Oct 28, 2025

Amrize Ltd reported a 6.6% increase in third-quarter revenue, driven by strong demand in infrastructure and commercial markets, despite challenges like a temporary equipment outage in its cement network. The company is raising its 2025 revenue guidance and continues to invest in organic growth projects to expand production and improve efficiency, positioning itself to capitalize on long-term demand in its $200 billion addressable market.

The most recent analyst rating on (AMRZ) stock is a Buy with a $48.20 price target. To see the full list of analyst forecasts on Amrize Ltd stock, see the AMRZ Stock Forecast page.

Amrize Ltd to Release Q3 2025 Financial Results on October 28
Oct 9, 2025

Amrize Ltd has announced that it will release its third quarter 2025 financial results on October 28, 2025, after the U.S. market closes, with a live webcast scheduled for the following day. This announcement is significant for stakeholders as it provides an opportunity to assess the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (AMRZ) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Amrize Ltd stock, see the AMRZ Stock Forecast page.

Amrize Advises Against TRC Capital’s Mini-Tender Offer
Aug 28, 2025

Amrize Ltd has advised its shareholders to reject an unsolicited mini-tender offer from TRC Capital Investment Corporation, which aims to purchase a small percentage of Amrize’s ordinary shares at a price below the current market value. The company warns that such offers can catch investors off guard, potentially leading them to sell their shares at below-market prices, and highlights that the offer is subject to several conditions. Amrize encourages shareholders to seek current market quotations and consult financial advisors before making decisions.

The most recent analyst rating on (AMRZ) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Amrize Ltd stock, see the AMRZ Stock Forecast page.

Amrize Ltd Reports Resilient Q2 2025 Performance
Aug 12, 2025

Amrize Ltd, a prominent player in the construction materials industry, offers advanced branded solutions for professional builders across North America, with a significant presence in both the U.S. and Canada. The company recently completed a successful spin-off and listing on the NYSE and SIX, marking a new chapter in its growth journey.

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
Amrize Ltd Reports Q2 2025 Financial Results
Positive
Aug 6, 2025

Amrize Ltd reported its second quarter 2025 financial results, highlighting a successful spin-off and listing on the NYSE and SIX on June 23. Despite challenging market conditions, the company maintained stable revenue and strong margins, supported by public sector infrastructure spending and commercial investments. The launch of the ASPIRE program aims to achieve over $250 million in synergies by 2028, enhancing margins and operational efficiencies. Amrize is investing in growth through acquisitions and capacity expansions, including acquiring Langley Concrete Group, Inc., and opening a new quarry in Oklahoma. The company has secured a strong investment-grade balance sheet, positioning it for long-term growth within a $200 billion addressable market.

The most recent analyst rating on (AMRZ) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Amrize Ltd stock, see the AMRZ Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025